Subject(s)
Disease Outbreaks , Tomography, X-Ray Computed , Tuberculosis , Child , Humans , Tuberculosis/diagnosisABSTRACT
Background: The buccal fat pad (BFP) has prompted numerous publications in anatomy, reconstructive and aesthetic surgery over the years; however, description of surgical treatment of pathologic conditions affecting this space is rare, especially in children. An extensive search of the English literature retrieved only five lipomas and one hemangioma in this age group.Methods: The authors report on two of these exceptional pediatric tumors of the BFP: one lipoma and one hemangioma referred to the outpatient clinic for diagnosis and treatment.Results: Both children had a similar clinical presentation and a characteristic MR image. The two lesions were excised through an intraoral approach, which proved to be a fast, safe and effective technique.Conclusions: Being extremely rare, tumors of the BFP in children have an indicative clinical presentation and radiologic image. A detailed intraoral approach is described and proposed as effective and safe surgical treatment.
Subject(s)
Adipose Tissue , Cheek , Facial Neoplasms/diagnosis , Hemangioma/diagnosis , Lipoma/diagnosis , Child , Facial Neoplasms/surgery , Female , Hemangioma/surgery , Humans , Lipoma/surgeryABSTRACT
INTRODUCTION: Fibrous hamartoma of infancy is a rare soft tissue tumour that usually appears before 2 years of age, typically in the upper extremities of male infants. CASE REPORT: We report the case of a 2 year old boy with a large and rapidly growing tumour in the upper extremity. COMMENTS: We describe the case, its differential diagnosis and the immunhistological characteristics, and we discuss the non-aggressive surgical treatment, based on the benign behaviour of this tumour.
INTRODUCCION: El hamartoma fibroso de la infancia es un raro tumor de partes blandas, que aparece antes de los 2 años de edad, típicamente en varones, en las extremidades superiores. CASO CLINICO: Presentamos el caso de un niño de 2 años con una gran masa de crecimiento rápido en miembro superior. COMENTARIOS: Se realiza descripción del caso, del diagnóstico diferencial y de sus características inmunohistológicas y se discute el tratamiento quirúrgico no agresivo, basado en el comportamiento benigno del tumor.
Subject(s)
Hamartoma/diagnosis , Soft Tissue Neoplasms/diagnosis , Child, Preschool , Diagnosis, Differential , Hamartoma/pathology , Hamartoma/surgery , Humans , Male , Soft Tissue Neoplasms/pathology , Soft Tissue Neoplasms/surgery , Upper ExtremityABSTRACT
Introducción. El hamartoma fibroso de la infancia es un raro tumor de partes blandas, que aparece antes de los 2 años de edad, típicamente en varones, en las extremidades superiores. Caso clínico. Presentamos el caso de un niño de 2 años con una gran masa de crecimiento rápido en miembro superior. Comentarios. Se realiza descripción del caso, del diagnóstico diferencial y de sus características inmunohistológicas y se discute el tratamiento quirúrgico no agresivo, basado en el comportamiento benigno del tumor (AU)
Introduction. Fibrous hamartoma of infancy is a rare soft tissue tumour that usually appears before 2 years of age, typically in the upper extremities of male infants. Case report. We report the case of a 2 year old boy with a large and rapidly growing tumour in the upper extremity. Comments. We describe the case, its differential diagnosis and the immunhistological characteristics, and we discuss the non-aggressive surgical treatment, based on the benign behaviour of this tumour (AU)
Subject(s)
Humans , Male , Child, Preschool , Hamartoma/diagnostic imaging , Hamartoma/surgery , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/surgery , Upper Extremity/pathology , Upper Extremity/surgery , Diagnosis, Differential , Immunohistochemistry/methodsABSTRACT
Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving >40 days who engrafted and were discharged without prior IFD. All patients who received ⩾20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to construct a post-engraftment IFD risk score. The 1-year CI of IFD was 11%. The non-relapse mortality was 40% in those developing IFD and 16% in those who did not. The intent-to-treat analysis showed that 17% of patients abandoned the assigned prophylaxis. Age >40 years, ⩾1 previous SCT, pre-engraftment neutropenia >15 days, extensive chronic GVHD and CMV reactivation were independent risk factors. The post-engraftment IFD score stratified patients into low risk (0-1 factor, CI 0.7%), intermediate risk (2 factors, CI 9.9%) and high risk (3-5 factors, CI 24.7%) (P<0.0001). The antifungal prophylaxis strategy failed to prevent post-engraftment IFD in 11% of alloSCT. Our risk score could be useful to implement risk-adapted strategies using antifungal prophylaxis after engraftment.
